Mesoblast hit with shareholder class action over stem cell treatment

Class Actions 2022-05-19 4:16 pm By Sam Matthews | Melbourne

Regenerative medicine company Mesoblast is facing another class action over claims it misled shareholders about the potential application of a developmental stem cell product to treat terminally ill children.